Blinatumomab: The Bispecific Antibody for Leukaemia

It links a leukaemia cell to a T cell. One end of the molecule binds CD19, a marker carried on B cells. The other binds CD3 on the patient’s own T cells. Held side by side, the T cell recognises the leukaemia cell and destroys it. The drug itself kills nothing.

That is what “bispecific” means here: two binding ends, two different targets, one purpose. The formal class name is a bispecific T-cell engager, usually shortened to BiTE. Blinatumomab was the first of them licensed in cancer, and the design is deliberately minimal — it is a fragment of two antibodies joined together, small enough to move quickly and cleared just as quickly. That last fact shapes everything about how it has to be given.

Families are usually told this is “a new injection” or “an antibody”. It is immunotherapy. Nobody says so, because the word has come to mean checkpoint inhibitors for solid tumours, and this molecule works nothing like those. The principle is the same one: the treatment does not attack the cancer itself, it puts the patient’s own immune cells in a position to do it.

Whether it applies at all is decided by one line on the immunophenotyping or flow cytometry report — whether CD19 is present on the leukaemia cells. The word “leukaemia” on a discharge summary is not enough. Acute myeloid leukaemia, for instance, does not carry CD19, and no amount of availability makes this molecule relevant there.

Because the molecule is cleared from the blood within hours. Its half-life in adults is only a couple of hours in the product labelling. A short daily drip would leave T cells disengaged for most of the day. So the dose runs without a break — 28 days at a time, through a small pump the patient carries everywhere.

This is the part almost nobody prepares families for. A parent or a spouse hears “infusion” and pictures a morning in a day-care chair. What actually arrives is a programmable, lockable pump in a pouch, connected through a central line, running for four weeks straight: into the shower, into bed, to the toilet, to the temple, into whatever sleeping arrangement the household had before. The medicine is not the shock. The pump is.

1. A central line goes in first. A PICC or a tunnelled line, because the pump needs dependable venous access for weeks, not days.
2. The first days are spent in hospital. The labelling sets this out by setting — see the table below.
3. The pump then goes home. It is programmable and lockable, and it runs at a fixed rate that nobody at home adjusts.
4. Bags are changed on a schedule. Preparations exist for 24-hour, 48-hour, 72-hour, 96-hour and 7-day bag changes. The longer-duration bags contain a preservative and are not used in the smallest infants.
5. The line is never flushed. Flushing would push a bolus of drug in at once. The labelling instructs against it, and only trained staff handle the line.
6. 28 days on, then a break. A cycle is 28 days of continuous infusion followed by a treatment-free interval — commonly 14 days, and 56 days in the continued-therapy phase for relapsed or refractory disease.

Two practical consequences follow from that table, and both are worth raising before the first bag is hung rather than during it. One adult has to be available at home for the whole cycle — not for emergencies, but for the ordinary business of living alongside someone attached to a pump. And the family needs to be within manageable reach of the treating unit for four weeks at a stretch, because bag changes, line care and any interruption all bring the patient back.

Ask, at the planning stage: who changes the bags and where, what happens if the pump alarms at 2 a.m., and how close to the hospital the family has to stay for the month. These are answerable questions, and the answers change what the month looks like far more than the drug does.

Cytokine release syndrome is what can follow when many T cells are switched on at once. Fever, chills, a fast pulse, falling blood pressure, breathlessness. It is one of two boxed warnings on blinatumomab. It is most likely in the first days of the first cycle, which is precisely why those days are spent in hospital.

Two things are built into the schedule to reduce it. Dexamethasone is given before the first dose of a cycle, before a step-up in dose, and when restarting after an interruption. And the first cycle uses a lower starting dose for the first days before stepping up, so the immune system meets the drug gradually rather than all at once.

If severe CRS occurs, the infusion is interrupted until it settles and corticosteroids are given; life-threatening CRS means the medicine is stopped permanently. None of this means something has gone wrong. It is the managed part of a treatment whose entire mechanism is deliberate immune activation.

CRS is also not the same event as the infusion reaction familiar from older antibody drips, which has a different cause and a different time course — Infusion Reactions With Antibody Medicines: What to Expect sets out that comparison.

At home, a temperature of 38 °C or more, new confusion or difficulty speaking, a seizure, breathlessness, or a rapid drop in alertness means going back to the treating unit or to the nearest emergency department the same day, without waiting for the next scheduled visit. Take the pump, the bag and the treatment record: the receiving doctor needs to know what is running and when it started.

Handwriting is used as a monitoring test on this drug for a reason. A caregiver who notices that the writing has changed, or that words are coming out wrong, has spotted something before any machine will.

Almost everyone with cancer, including almost everyone reading about immunotherapy. Blinatumomab acts only where CD19 sits on the surface of the cancer cell. In practice that means B-cell acute lymphoblastic leukaemia and nothing else.

It is not a treatment for solid tumours — breast, lung, colorectal, prostate, head and neck, cervical or ovarian cancer. It is not used in acute myeloid leukaemia, in chronic myeloid leukaemia, in myeloma, or in most lymphomas. And it is not an alternative to a checkpoint inhibitor: different target, different disease, different mechanism entirely.

Even inside CD19-positive B-ALL it is not for everyone. It is not started during an active severe infection. It is not appropriate where relapsed leukaemia has lost CD19, which is a recognised escape route after CD19-directed treatment and the reason the marker is rechecked at relapse rather than assumed. Existing neurological disease or a history of seizures is weighed carefully, because neurological toxicity is a boxed warning. Pregnancy, contraception and breastfeeding need an explicit conversation before the first cycle. Driving and operating machinery are out for the duration. The longer-duration preserved bags are not used in the smallest infants.

There is also a practical exclusion that deserves saying plainly rather than being discovered three weeks in. Because the medicine is not routinely marketed in India, it can realistically be considered only where a family has a workable route to a named-patient import and a realistic way to fund a full course. A treatment that stops halfway through a cycle for want of the next shipment is worse than one that never started.

Asking whether a CD19-directed option exists for a specific relapsed B-ALL is a reasonable question for a haematologist. Asking for this molecule because it is described as immunotherapy, in a disease that does not carry CD19, is not.

Not as a routinely marketed product, as of August 2026. Blinatumomab is approved by the US FDA, the European Medicines Agency and Japan’s PMDA. Published Indian access sources describe it reaching patients here through the named-patient import route under CDSCO permits, rather than as a brand held in stock.

Named-patient import is a real and legitimate pathway, not a workaround. In outline: the treating haematologist documents why no marketed alternative is suitable for this patient; a licensed importer or the hospital applies for the CDSCO permit — Form 12A covers small quantities imported for a named patient’s personal use, with Form 12B and a CDEC used on the licensed-importer route; and the medicine is shipped under cold chain with its import documentation. That paperwork is why the timeline is measured in weeks rather than days, which matters a great deal in an acute leukaemia.

Four things are worth insisting on in writing before money moves: the CDSCO permit reference, the bill of entry and invoice, the batch number with the manufacturer named, and the cold-chain record from despatch to delivery. Any imported biologic without that paper trail should be refused. The same reasoning is set out in more detail in how to check that an immunotherapy vial is genuine and in the guidance on cold chain and storage for immunotherapy medicines.

Regulatory status changes. If a treating team says a locally marketed version is now available, confirm it against CDSCO records through the hospital rather than against a supplier’s website, and treat the date on this page as the limit of what it can tell you.

There is no Indian MRP for a product that is not routinely marketed here. Reported import listings in August 2026 quote roughly ₹1.5–1.7 lakh for a single 35 microgram vial. A published US list price of about US$5,700 per vial is widely cited. A course needs many vials across several cycles.

The single most useful thing a family can obtain here is a written quotation for the whole planned course — number of cycles, vials or bags per cycle, import charges, line and pump, and the hospital days — rather than a per-vial price. With an imported medicine the drug line and the hospital line come from two different organisations, and a figure quoted by one of them is routinely mistaken for the total.

On schemes and insurance, expect to have to ask rather than assume. Government scheme packages and many insurance policies are written around medicines approved and marketed in India, and an imported unapproved product commonly falls outside them for exactly that reason. Get the position confirmed in writing before the first cycle, not after it. Immunotherapy Medicines Explained sets out how approval status, brand and reimbursement interact across this whole group of drugs.

No — same target, different treatment. Both act against CD19 on B-cell leukaemia. CAR-T re-engineers the patient’s own T cells once, in a laboratory, and returns them as a single infusion. Blinatumomab does the linking chemically, from a bag, for as long as the pump runs.

CION Cancer Clinics does not provide CAR-T or any cell therapy. Where a haematologist raises it, the role here is referral and orientation only — the treatment itself happens at a licensed CAR-T centre, and the CAR-T referral pathway in India describes how that referral actually runs.

Blinatumomab is also not the only antibody-based medicine used in blood cancer, and the others are not interchangeable with it, because each is built around a different marker. Obinutuzumab acts on CD20 in lymphoma and chronic lymphocytic leukaemia. Polatuzumab vedotin is an antibody-drug conjugate that carries chemotherapy to CD79b in lymphoma. Which one is discussed, if any, follows from the immunophenotype and the diagnosis, never from which sounds most advanced.

• Infusion Reactions With Antibody Medicines: What to Expect — how an infusion reaction differs from cytokine release syndrome.
• Obinutuzumab: Uses and Availability in India — the CD20 antibody used in lymphoma and CLL.
• Polatuzumab Vedotin: Uses and Availability in India — the CD79b antibody-drug conjugate.
• Immunotherapy Medicines Explained — the index of antibodies, checkpoint inhibitors and biosimilars.
• Immunotherapy at a glance — what this family of treatments does, and what it does not.

Editorial information about a prescription-only medicine — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Clinical statements follow the product labelling and published NCCN guidance; approval, availability and pricing statements are indicative and dated to August 2026, and regulatory status can change. Whether blinatumomab applies to a particular patient, and in which phase of treatment, is a decision for the treating haematologist-oncologist.